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several large-scale longitudinal studies have reported a relation-
ship between cannabis use in adolescence and later symptoms 
of psychosis in the normal population (Tien and Anthony, 1990; 
Arseneault et al., 2002; van Os et al., 2002; Fergusson et al., 2003; 
Stefanis et al., 2004; Ferdinand et al., 2005; Henquet et al., 2005a). 
In one study, cannabis use at age 18 and 21 led to 3.7 and 2.3 higher 
rates of psychotic symptoms, respectively (Fergusson et al., 2003). 
The relationship between cannabis and schizophrenia seems fairly 
speciﬁ  c to schizophrenia, as compared to other mental disorders 
(Chambers et al., 2001; Degenhardt et al., 2007; Di Forti et al., 
2007; Moore et al., 2007), and cannot be explained by potentially 
confounding factors, like premorbid disorders, drug use, intoxica-
tion, personality traits, sosiodemographic markers and intellec-
tual ability (Smit et al., 2004; Moore et al., 2007). Accordingly, ﬁ  ve 
recent reviews concluded with an increased risk for schizophrenia 
and psychosis in individuals who have used cannabis (Arseneault 
et al., 2004b; Macleod et al., 2004; Smit et al., 2004; Henquet et al., 
2005b; Semple et al., 2005; Moore et al., 2007).
An alternative explanation is what can be called reversed 
causality, namely that schizophrenia patients use cannabis as a 
form of self-medication, although existing data does not seem 
to support this hypothesis (Chambers et al., 2001). An impor-
tant argument against reversed causality is an “order-effect”; i.e. 
cannabis use seems to occur before the outbreak of psychosis, 
and not the other way around (Linszen et al., 1994; Degenhardt 
et al., 2007; Corcoran et al., 2008). Furthermore, in contrast to a 
self-medication hypothesis, the psychoactive substance in can-
nabis, delta-(9)-tetrahydrocannabinol (THC), increases, and not 
decreases, anxiety (Fusar-Poli et al., 2009; Morrison et al., 2009). 
Several studies have also shown that THC increases symptoms 
INTRODUCTION
A history of cannabis use is more common in schizophrenia than in 
the normal population (Regier et al., 1990; Arseneault et al., 2004b; 
Barnes et al., 2006). Life-time cannabis use has been reported to be 
as high as 64.4% in patients with schizophrenia (Barnes et al., 2006), 
and Løberg et al. (2003) found that 45% of schizophrenia patients 
participating in research studies had a history of previous cannabis 
use. Since cannabis may be a risk factor for schizophrenia, mediated 
through changes in brain functioning and biochemistry, cannabis 
may also have an effect on cognitive functioning in this patients 
group. In a preliminary study in our laboratory we were struck 
by apparent paradoxical positive effects of cannabis on cognition 
in patients with schizophrenia (Løberg et al., 2003, 2008). These 
preliminary ﬁ  ndings prompted a review of the existing literature on 
the relationship between cannabis use and cognitive functioning in 
schizophrenia. For this purpose, we found 23 studies (see Table 1) 
that have looked at the relationship between cannabis use and cog-
nitive impairments in schizophrenia. The results from the review 
are discussed and possible explanations suggested.
CANNABIS USE – A RISK FACTOR FOR SCHIZOPHRENIA?
Longitudinal studies have reported an increased risk for schizo-
phrenia and other psychoses after cannabis use. In two large-
scale Swedish studies, the same cohort of about 50 000 military 
conscripts were for followed longitudinally over 15 and 26 years. 
Dose-dependent relationships were found between cannabis use at 
18 years of age and a later diagnosis of schizophrenia (Andreasson 
et al., 1987; Zammit et al., 2002). Cannabis have also been shown 
to increase the rate of conversion to psychosis in individuals at risk 
for psychosis (Kristensen and Cadenhead, 2007). Furthermore, 
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of psychosis and   cognitive   impairments (D’Souza et al., 2005; 
Morrison et al., 2009), with a possible increased sensitivity in 
schizophrenia to the adverse effects of THC (D’Souza et al., 2004). 
Moreover, cannabis has been shown to have clinical signiﬁ  cance. 
Cannabis use in schizophrenia can lead to worsened illness prog-
noses; worsened clinical outcome, longer psychotic episodes, more 
relapse and re-hospitalizations, poorer social functioning, more 
frequent relapses, poorer compliance, and increased   treatment 
needs (Linszen et al., 1994; Caspari, 1999; Grech et al., 2005). Thus, 
taken together, the available data seem to point to cannabis use as 
increasing psychotic symptoms, and increasing the vulnerability 
for a psychotic outbreak. For example, Moore and colleagues have 
argued that we now know enough to warn young people about the 
risk for psychosis after cannabis use (Moore et al., 2007).
However, most individuals do not develop schizophrenia after 
cannabis use, suggesting that a heightened risk for a development 
of psychosis must be related to other vulnerability factors. Verdoux 
(2004) found that subjects with established vulnerability for psycho-
ses showed a stronger risk of follow-up psychosis after cannabis use 
than individuals without such vulnerability. The relationship between 
 cannabis use and psychosis may also be genetically mediated. In a lon-
gitudinal study of 803 individuals, an interaction between the Val allele 
of the Catechol-O-methyltransferase (COMT) gene and adolescent 
cannabis use signiﬁ  cantly increased the likelihood of exhibiting psy-
chotic symptoms and the development of schizophreniform disorders 
(Caspi et al., 2005). In accordance with this, an interaction between 
the COMT Val allele and sensitivity for psychosis and cognitive effects 
of the psychoactive substance in cannabis has been found in individu-
als with psychosis and their relatives (Henquet et al., 2006, 2009).
CANNABIS AND BRAIN FUNCTION
The relationship between cannabis and schizophrenia may be 
attributed to effects of cannabis on brain functioning and bio-
chemistry. The endogenous cannabinoid system may directly or 
Table 1 | Overview of 23 studies on the effects of cannabis/drug use in schizophrenia and related psychoses on cognition by n, drug type, 
diagnoses, type of drug use, and results.
n: drug group/no-  Multiple drugs  Diagnostic characteristics  Current or former  Cognitive results:  Reference
drug group  or cannabis    drug use, SUD if  drug group versus 
     diagnosed  no-drug group 
33/33 (13 in no-drug  Multiple drugs  Schizophrenia (outpatients)  Current (SUD)  No difference  Addington and
group had former         Addington (1997)
drug use)        
110/42 Multiple  drugs  Schizophrenia  + schizophreniform Both  No  difference  Barnes et al. (2006)
22 (moderate); 16  Multiple drugs  Schizophrenia  Former   No difference  Cleghorn et al. (1991)
(severe)/25        
18/59  Cannabis  Non-affective  Current (SUD)  Minimal difference  Liraud and Verdoux (2002)
   psychoses + mood disorder    
128/138  Multiple drugs  First episode psychoses  Current (SUD)  No difference  Pencer and Addington (2003)
14/13 Cannabis  Schizophrenia  + schizoaffective  Current (SUD)  No difference  Sevy et al. (2007)
21/23 Multiple  drugs  Schizophrenia  + schizoaffective  Current  Minimal difference  Wobrock et al. (2007)
   (recent onset)   
27/23  Multiple drugs  Schizophrenia (paranoid type)  Current (SUD)  Minimal difference  Thoma and Daum (2008)
15 (current); 26  Multiple drugs  Psychiatric outpatients  Both (SUD)   Better in both drug  Carey et al. (2003)
(former)/15       groups 
44/15 Cannabis  Schizophrenia  + schizoaffective  Both  Better in drug group  Coulston et al. (2007a)
46/43  Multiple drugs  Schizophrenia (inpatients)  Current (SUD)  Better in drug group  Herman (2004)
19/20  Cannabis  Schizophrenia  Former  Better in drug group  Jockers-Scherubl et al. (2007)
16/14  Multiple drugs  Schizophrenia (men only)  Current (SUD)  Better in drug group  Joyal et al. (2003)
12/16 Cannabis  schizophrenia  + schizoaffective  Former  Better in drug group  Kumra et al. (2005)
   (adolescent)    
13/13  Cannabis  Acute psychoses  Current  More improved in drug  Løberg et al. (2008)
       group 
13/16  Cannabis  Schizophrenia  Former  Better in drug group  Løberg et al. (2003)
57 (mild); 35  Multiple drugs  First episode psychoses  Current  Better in both drug  McCleery et al. (2006)
(severe)/91     (severe = SUD)  groups 
44/32 Multiple  drugs  Schizophrenia  + schizoaffective  Current (SUD)  Better in drug group  Potvin et al. (2005)
35/34 Cannabis  Schizophrenia  + schizoaffective  Former (SUD)  Better in drug group  Schnell et al. (2009)
27/91 Multiple  drugs  Schizophrenia  + schizoaffective  Both (SUD)  Better in drug group  Sevy et al. (2001)
26/37  Cannabis  First episode psychoses  Both  Better in drug group  Stirling et al. (2005)
27/23  Multiple drugs  Schizophrenia  Current (SUD)  Better in drug group  Thoma et al. (2007)
61/71  Cannabis  Non-affective psychoses  Former  Better in no-drug group   Mata et al. (2008)Frontiers in Human Neuroscience  www.frontiersin.org  November 2009  | Volume 3  |  Article 53  |  3
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 indirectly be involved in the development of the effects of cannabis 
on symptoms of psychosis and cognition (Solowij and Michie, 
2007). THC affects cannabinoid receptors, which are distributed 
with high density in the cerebral cortex, including brain regions 
implicated in schizophrenia (D’Souza et al., 2005). The endog-
enous cannabinoid system interacts with the dopaminergic system 
of the brain, and THC inﬂ  uence dopamine synthesis and uptake 
(D’Souza et al., 2005). Abnormalities of the endogenous cannabi-
noid system in schizophrenia, not caused by cannabis use, have also 
been reported. Increased levels of endogenous cannabinoids have 
been found in the frontal cortex (Dean et al., 2001), in addition to 
elevated levels of endogenous cannabinoids in the cerebral spinal 
ﬂ  uids (Leweke et al., 1999).
A stronger relationship between adolescent cannabis use and 
psychosis or schizophrenia, as compared to adult use, has been 
reported in several studies (Caspi et al., 2005; Konings et al., 2008). 
Even though some of these ﬁ  ndings can be explained by an increased 
cumulative exposure to cannabis with earlier onset of cannabis use, 
it may also suggest that a developing brain is more vulnerable to 
the effects of cannabis than a matured brain.
However although there seems to be ample evidence for 
the inﬂ  uence of cannabis on the development and outbreak 
of psychosis or schizophrenia (Moore et  al., 2007), possibly 
mediated by adverse effects on brain functioning acting on the 
dopaminergic system (D’Souza et al., 2005), much less is known 
regarding the effects of cannabis use on cognitive functioning in 
schizophrenia. If cannabis inﬂ  uences schizophrenia neurodevel-
opment and brain functioning, it could be expected that can-
nabis use may impact on cognitive functioning in this patients 
group. The aim of the present review was therefore to examine 
the relationship between cannabis use and cognitive functioning 
in schizophrenia.
COGNITION IN PATIENTS WHO USE CANNABIS – A PARADOX
Cognitive impairment is now universally recognized as a core feature 
of schizophrenia, and clinically relevant cognitive impairments are 
observed in a majority of patients with schizophrenia (Green, 1996; 
Palmer et al., 1997, 2009). Cognitive impairment is often observed 
before the development of psychosis and in close relatives, and cog-
nitive symptoms may also reside after clinical symptoms have been 
reduced or are no longer seen (Neuchterlein et al., 1994; Weinberger, 
1995; Heaton et al., 2001; Gschwandtner et al., 2003), Thus, it is 
clear that eventual effects of cannabis use on cognitive functioning 
in schizophrenia would be of both theoretical value for the under-
standing of the disorder, and of clinical relevance for the diagnosis 
and treatment of the disorder. Intuitively, a worsened outcome on 
cognitive functioning would be expected after cannabis use, since 
cannabis has negative effects on psychosis in general, and from ﬁ  nd-
ings that cannabis use impairs illness prognosis (Linszen et al., 1994; 
Caspari, 1999; Grech et al., 2005), in addition to the adverse effects 
of cannabis on brain functioning (D’Souza et al., 2004).
For this purpose we reanalyzed previously collected data in our 
laboratory on cognitive performance in schizophrenia patients, 
including cannabis use as an explanatory variable (data from Løberg 
et al., 2003, 2008). Information on the history of cannabis use was 
based on the patients’ clinical records and therapist questionnaires, 
and was further validated through SCID-interviews. Surprisingly, 
we found that patients with schizophrenia who had a history of 
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FIGURE 1 | Mean T-scores for the cannabis and no-cannabis group for the 
ﬁ  ve cognitive functions. General abilities = general verbal and visuospatial 
abilities = WAIS (Information, Vocabulary, Block Design), Verbal Fluency (FAS), 
Rey-Osterrieth Complex Figure test, Wisconsin Card Sorting Test (WCST).  
Learning/memory = California Verbal Learning Test (CVLT) II, Rey-Osterrieth 
Complex Figure Test. Attention/working mem. = attention/working memory = 
Digit Vigilance Test, Calcap Continuous Performance Test (CPT), Trail Making Test 
B. Execute functions = Wisconsin Card Sorting Test (WCST), Stroop Test. 
Psychomotor speed = Trail Making Test A, Grooved Pegboard Test, 
Fingertapping Test.Frontiers in Human Neuroscience  www.frontiersin.org  November 2009  | Volume 3  |  Article 53  |  4
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cannabis use scored signiﬁ  cantly above their fellow counterparts 
without a history of cannabis use (see Figure 1). This was found 
for almost all cognitive functions investigated, such as general intel-
lectual ability, executive functions, attention, working memory and 
psychomotor speed. These results did not change when other illegal 
drugs where controlled for, and there were no differences in the two 
groups with regard to clinical variables (Løberg et al., 2003).
In a second, prospective, study of patients with acute psychosis 
we assessed cognitive function at admission to a psychiatric emer-
gency ward, after 6 weeks, and after 3 months. Information on the 
history of cannabis use was based on patient’s clinical records and 
the Clinician Drug Use Scale (Drake et al., 1990), and was further 
validated through urine samples. The patients with both cannabis 
use and psychosis showed a signiﬁ  cantly larger improvement in 
their cognitive performance in the three months after admission, 
as compared to the psychotic patients with no cannabis use. Both 
groups showed cognitive impairments at admission, but these were 
more prevalent in the non-cannabis psychosis group (see Figure 2; 
Løberg et al., 2008).
COGNITION IN PATIENTS WHO USE CANNABIS – A 
LITERATURE REVIEW
The paradoxical results reported by Løberg et al. (2003, 2008) 
seem to be consistent with several other studies on the rela-
tionship between cognition, cannabis and/or illegal drugs and 
schizophrenia (Joyal et al., 2003; Jockers-Scherubl et al., 2007). 
We performed a PubMed search on all combinations of the fol-
lowing search words: cannabis, substance, schizophr*, psychos*, 
cognit* and neuropsych*, and searched the reference lists for all 
included papers of other studies covering this topic. This resulted 
in 23 studies comparing schizophrenia and related psychoses 
with and without cannabis use (alone or in combination with 
other substances) on cognitive performance (see Table 1 for 
further details).
Fourteen of the studies listed in Table 1 reported that the 
cannabis groups showed better cognitive performance than the 
no-  cannabis groups (Sevy et al., 2001; Carey et al., 2003; Joyal 
et al., 2003; Løberg et al., 2003, 2008; Herman, 2004; Kumra 
et al., 2005; Potvin et al., 2005; Stirling et al., 2005; McCleery 
et al., 2006; Coulston et al., 2007a; Jockers-Scherubl et al., 2007; 
Thoma et al., 2007; Schnell et al., 2009). Eight of the studies in 
Table 1 reported no or minimal differences in cognitive per-
formance in the two groups (Cleghorn et al., 1991; Addington 
and Addington, 1997; Liraud and Verdoux, 2002; Pencer and 
Addington, 2003; Barnes et al., 2006; Sevy et al., 2007; Wobrock 
et al., 2007; Thoma and Daum, 2008), and one study reported 
better cognitive performance in the no-cannabis compared to 
the drug group (Mata et al., 2008).
Most of the studies in Table 1 have small “n”, and may there-
fore be inﬂ  uenced by Type-II statistical errors (false negatives), 
underestimating group differences due to lack of power. For 
instance, Thoma and Daum (2008) suggested that this may have 
been a problem in their 2008 study, inﬂ  uencing their conclu-
sion of no differences between the groups. Furthermore, some 
of the studies included diverse drug use in addition to cannabis 
use, for instance alcohol and opiates in clusters of stimulating 
and/or hallucinatory illegal drugs. These drugs may have differ-
ent, and sometimes opposite effects on brain functioning and 
neurochemistry, and consequently on cognition. In the overview 
in Table 1, all studies included cannabis; as a high frequent drug 
together with other drugs used, or as the only drug used. Thus, no 
study was included that did not include cannabis. Previous drug 
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FIGURE 2 | Mean neuropsychological T-scores for the cannabis and no-cannabis group at admission, after 6 weeks and 3 months.Frontiers in Human Neuroscience  www.frontiersin.org  November 2009  | Volume 3  |  Article 53  |  5
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use versus current drug use is included in Table 1 as a separate 
factor since this may have inﬂ  uenced the results. Current drug 
use may inﬂ  uence cognition by means of persisting intoxication 
effects or more acute effects on brain functioning, thus creating a 
“false” cognitive impairment not otherwise present. Furthermore, 
the use of diagnostic criteria is noted, yielding a SUD, since this 
usually means that the patients meet criteria for abuse or addic-
tive behavior, and that the drug use has negative consequences 
for everyday living. This may bias the drug groups to consist of 
quite heavy users due to the exclusion of patients without a SUD 
diagnosis who nevertheless may have a frequent drug problem. 
An example of this is the study by Addington and Addington 
(1997) where it was reported that the no-drug group actually 
included 13 patients with previous drug use. Another problem 
when comparing the studies in Table 1 is the different diagnostic 
groups included in the studies, possibly with different levels of 
cognitive vulnerability.
Coulston et al. (2007b) did not ﬁ  nd consistent neuropsycho-
logical patterns of cannabis use on cognition when examining 
seven studies (one of these studies reported intoxications effects, 
though), and attributed this to methodological variability between 
and methodological limitations within the studies. Methodological 
and clinical heterogeneity is also a problem in studies comparing 
differences in brain structure and function between drug and no-
drug groups by means of brain-imaging methods, and inconsistent 
results have been reported (Quickfall and Crockford, 2006; Rais 
et al., 2008; Wobrock et al., 2009).
CONCLUSION LITERATURE REVIEW
Table 1 show that a majority of the studies report better cogni-
tive functioning in the cannabis-related schizophrenia and psy-
chosis groups compared to non-drug groups. This conclusion 
is supported even when confounding factors, like age, years of 
education, premorbid IQ, medical history, substance use, and 
psychiatric symptoms (Coulston et  al., 2007a) are controlled 
for. Likewise, Potvin et al. (2008) argued that most studies have 
shown superior neuropsychological functioning in cannabis use 
and schizophrenia combined, then in schizophrenia patients alone 
(Potvin et al., 2008).
EXPLANATIONS FOR THE PARADOXICAL EFFECT
The seemingly paradoxical cognitive ﬁ  ndings in cannabis-related 
schizophrenia could have several explanations. One explanation is 
that the group differences in cognition are attributed to superior 
social skills in the cannabis schizophrenia groups, making them 
“skillful” enough to get hold of illegal drugs. Superior social skills 
are however not consistent with the ﬁ  nding of poorer prognosis in 
this group. Few studies have, however, examined this directly, and the 
issue therefore remains unresolved. Two Norwegian studies reported 
poorer premorbid functioning in psychosis patients who also abused 
illegal drugs (Ringen et al., 2008), and better premorbid social func-
tioning and poorer premorbid academic functioning in this group 
(Larsen et al., 2006), respectively. It has also been suggested that the 
group differences could be caused by cannabis having a protective 
or positive inﬂ  uence on brain functioning (Coulston et al., 2007a). 
Based on the effects of cannabis on brain function and prognosis of 
the psychosis, this is not supported by the existing data.
A second explanation could be that cannabis imitates the typi-
cal cognitive vulnerability seen in schizophrenia. The major psy-
choactive component in cannabis, THC, creates transient negative 
effects on cognitive functioning and psychotic symptoms (D’Souza 
et al., 2005; Semple et al., 2005; Morrison et al., 2009). Cannabis 
use of sufﬁ  cient magnitude, or in individuals particularly vulner-
able to the effects of cannabis, may lead to compromised brain 
functioning, causing a breakdown of reality testing. In addition, 
adolescent   cannabis use seems to cause an especially strong risk 
for later psychosis (Caspi et al., 2005; Konings et al., 2008), con-
sistent with a sensitive adolescent brain in the middle of impor-
tant neurodevelopmental processes. Thus, cannabis would induce 
more transient cognitive changes that mimic the typical cognitive 
vulnerability. These changes can cause psychosis for some indi-
viduals, but will normally not cause the characteristic persistent 
cognitive impairments seen in schizophrenia. Consistent with this, 
fewer neurological soft signs have been shown in schizophrenia 
patients who also use cannabis (Bersani et al., 2002; Ruiz-Veguilla 
et al., 2009). Stirling et al. (2005) also reported fewer neurologi-
cal soft signs, and better cognitive functioning, in the drug group 
after 10–12 years, and suggested that the drug group followed a 
different path to schizophrenia with less negative events of early 
brain development.
Further support for the imitation of cognitive vulnerability 
hypothesis is ﬁ  ndings regarding age of onset of the disorder. 
The development of schizophrenia is usually seen in late adoles-
cence/early adulthood. This is in line with a neurodevelopmental 
model (Weinberger, 1995), since the age of onset coincides with 
the late maturation of the prefrontal cortex through pruning of 
exuberant synapses and myelination of axons (Woo and Crowell, 
2005). Studies have reported earlier age of onset in schizophrenia 
patients who have used cannabis (Stirling et al., 2005; Barnes 
et al., 2006). Consistent with this, data from our own laboratory 
showed four years earlier debut of schizophrenia in cannabis users 
(Løberg et al., 2003). Again, this suggests a different pathway to 
schizophrenia, and is consistent with a hypothesis stating that 
cannabis is an environmental factor imitating the effect of the 
typical cognitive vulnerability (Solowij and Michie, 2007).
CONCLUDING REMARKS
Cannabis seems to be a risk factor for the development of schizo-
phrenia, mimicking the typical cognitive vulnerability. As an 
environmental factor, cannabis use has the potential for being 
inﬂ  uenced by interventions, thus indirectly having an effect on the 
development of schizophrenia. Accordingly, clinical implications 
(Moore et al., 2007) and public health implications (Arseneault 
et al., 2004a) have been suggested. A promising clinical interven-
tion would be to monitor cannabis use in patients known to be vul-
nerable for psychosis, and help them to stay away from cannabis. 
Cannabis does not appear to create additive cognitive impairments, 
however, and cannabis-using patients may actually have better 
cognitive functioning. This could suggest that cannabis-related 
schizophrenia represents a different subtype, although few consist-
ent clinical differences in regard to symptom proﬁ  les have been 
found (Boydell et al., 2007). This necessitates a better understand-
ing of the paradox of better cognitive functioning, similar clinical 
proﬁ  les, and worse prognosis in this group, through for instance Frontiers in Human Neuroscience  www.frontiersin.org  November 2009  | Volume 3  |  Article 53  |  6
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longitudinal studies on the effect of previous and ongoing  cannabis 
use on the ﬂ  uctuations of cognitive and clinical functioning in 
schizophrenia.
Possibly cannabis mimics the typical cognitive vulnerability seen 
in schizophrenia. Solowij and Michie (2007) suggested that can-
nabis leads to similar cognitive impairment as what is  typically seen 
in schizophrenia, but of a lower magnitude. Several   studies have 
shown cognitive impairment during THC-intoxication (D’Souza 
et al., 2005; Morrison et al., 2009). The preliminary data from our 
own laboratory suggest more transient cognitive impairments in 
the cannabis group (Løberg et al., 2008). Perhaps cannabis causes 
a transient cognitive breakdown enabling the development of 
 psychosis, in spite of the absence of proper cognitive vulnerability. 
Thus, the effects of cannabis on cognition and brain functioning 
model the cognitive vulnerability in schizophrenia, and under-
standing this cognitive breakdown may provide a unique window 
to understanding schizophrenia neurodevelopment.
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